Search
Close this search box.

FETCH wins Venture Challenge Spring 2024!

The winner of the Venture Challenge was announced today at the Dutch Biotech Event. The proud winner of the 2024 spring edition is FETCH! The innovative startup has developed a groundbreaking approach for precision diagnostics in personalized medicine for metastatic cancer patients through tumor cell analysis from a large blood volume. This method can provide the crucial information needed to select the best targeted therapies, overcoming the limitations of traditional biopsies and current liquid biopsy methods.

The Venture Challenge Spring started in May and today at the Dutch Biotech Event. FETCH takes home the €25.000 prize money to invest in their growth. The other highly-motivated participating teams were: MaTiRex, Myonovum, QTM Biosciences, THRONCAT and Twente Medical Optics. QTM Biosciences is one of the tenants at Pivot Park. 

“The Venture Challenge helped us to get clarity on the core of our unique value and potential. This will allow us to focus on our strengths, but also address the potential pitfalls we identified during the program. With this, we can take the next step in revolutionizing oncologic care.” – Michiel Stevens, founder of FETCH. 

FETCH is initially focusing on metastatic prostate cancer and planning to broaden their application to other types of metastatic cancers. Their advanced immunomagnetic enrichment technique for circulating tumor cells (CTCs) from leukapheresis material is designed to be adaptable and scalable, which means it can potentially be applied to a wide range of cancers where current biopsy methods are impractical or insufficient. They are also looking to integrate their service into research programs. By doing so, FETCH is poised to contribute significantly to the field of personalized cancer treatment, offering a valuable tool for real-time tumor monitoring and targeted therapy selection.

Want to participate in the next venture challenge? Click here for more information. The call for the Venture Challenge Fall closes 2 July, 14:00 CEST, 2024! Apply here

Pivot Park Captains' Dinner

10 years ago, Pivot Park opened its doors to the world. Thanks to your commitment, support and confidence, we have been able to grow it into the successful and innovative biopharmaceutical campus it is today.

Now it’s time to celebrate!

We are therefore delighted to invite you – along with all your fellow CEOs at Pivot Park – to a special night out featuring inspiring art, a wonderful dinner and lots of opportunities to network and exchange ideas.

Erwin Wurm | Am I a House?

For the first time, the artist shows a cross-section of his work, from Narrow Furniture to One Minute Sculptures, within the walls of a historic building. Villa Constance, a former home that today houses Museum Jan Cunen, is not only a location but also part of the conversation. Because what exactly is a house?

#100YEARSPHARMAFUTURE

The development of medicines in Oss began one hundred years ago. It was then that the foundations were laid for what would become a flourishing pharmaceutical sector in the Netherlands, leading to groundbreaking discoveries such as insulin and the anti-conception pill.

Today, the entire chain is still represented in Oss, from early-stage research to the commercial scale production of medicines. Working in Oss, we focus on the health of people all over the world. Employees at dozens of companies large and small put their heart and soul into new medicines, products and services that will improve lives worldwide. Together, our strength lies in our combination of broad knowledge about the development of medicines and a thorough understanding of the requirements of high-quality production.

This shared past and common values stimulate strong bonds among everyone who works in pharmaceuticals in Oss. We build on qualities, expertise and networks that go back decades. And with a wide variety of pharmaceutical companies, suppliers and scientific institutions all located nearby, we offer an attractive business climate and an excellent basis for international collaboration.

We are proud to work together to create a better and healthier future for all, a collaboration that in turn fuels growing employment: today, most pharmaceutical jobs in the Netherlands are in Oss. Here we connect talent and companies and stimulate entrepreneurship, while our expert employees are our most important asset. Their drive ensures that Oss has an influence on health all over the world.

Pharma in Oss offers endless opportunities to startups and talent in a city and region that is a joy to live and work in. We are committed to collaboration and sustainable and successful entrepreneurship. Oss’s pharmaceutical companies are intrinsically competitive while also being committed to quality and safety. This, plus their focus on new health solutions and contemporary technology, makes us a leader in our pursuit of a better life for people worldwide.